share_log

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4: Statement of changes in beneficial ownership of securities-Officer Bligh James

4:持股變動聲明-高管 Bligh James
美股SEC公告 ·  06/11 17:58

Moomoo AI 已提取核心訊息

James Bligh, the Interim CFO of Conduit Pharmaceuticals, has acquired 37,272 shares of the company's common stock on June 11, 2024. The transaction, classified under the code 'A' for acquisition, was executed directly by Bligh. Following this transaction, Bligh's total direct holdings in the company amount to 37,272 shares. The acquisition is part of a grant, award, or other form of acquisition, as per the transaction details provided.
James Bligh, the Interim CFO of Conduit Pharmaceuticals, has acquired 37,272 shares of the company's common stock on June 11, 2024. The transaction, classified under the code 'A' for acquisition, was executed directly by Bligh. Following this transaction, Bligh's total direct holdings in the company amount to 37,272 shares. The acquisition is part of a grant, award, or other form of acquisition, as per the transaction details provided.
2024年6月11日,Conduit藥品公司代理首席財務官詹姆斯·布萊格直接收購了37272股公司普通股。這筆交易歸類於“A”類收購。此次收購後,布萊格在該公司的總直接持股量爲37272股。根據提供的交易細節,這次收購是作爲授予、獎勵或其他形式的收購的一部分。
2024年6月11日,Conduit藥品公司代理首席財務官詹姆斯·布萊格直接收購了37272股公司普通股。這筆交易歸類於“A”類收購。此次收購後,布萊格在該公司的總直接持股量爲37272股。根據提供的交易細節,這次收購是作爲授予、獎勵或其他形式的收購的一部分。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息